Dysautonomia in COVID-19 Patients: A Narrative Review on Clinical Course, Diagnostic and Therapeutic Strategies
Introduction
On March 11, 2020, the World Health Organization sounded the COVID-19 pandemic alarm. While efforts in the first few months focused on reducing the mortality of infected patients, there is increasing data on the effects of long-term infection (Post-COVID-19 condition). Among the different symptoms described after acute infection, those derived from autonomic dysfunction are especially frequent and limiting.
Objective
To conduct a narrative review synthesizing current evidence of the signs and symptoms of dysautonomia in patients diagnosed with COVID-19, together with a compilation of available treatment guidelines.
Results
Autonomic dysfunction associated with SARS-CoV-2 infection occurs at different temporal stages. Some of the proposed pathophysiological mechanisms include direct tissue damage, immune dysregulation, hormonal disturbances, elevated cytokine levels, and persistent low-grade infection. Acute autonomic dysfunction has a direct impact on the mortality risk, given its repercussions on the respiratory, cardiovascular, and neurological systems. Iatrogenic autonomic dysfunction is a side effect caused by the drugs used and/or admission to the intensive care unit. Finally, late dysautonomia occurs in 2.5% of patients with Post-COVID-19 condition. While orthostatic hypotension and neurally-mediated syncope should be considered, postural orthostatic tachycardia syndrome (POTS) appears to be the most common autonomic phenotype among these patients. A review of diagnostic and treatment guidelines focused on each type of dysautonomic condition was done.
Conclusion
Symptoms deriving from autonomic dysfunction involvement are common in those affected by COVID-19. These symptoms have a great impact on the quality of life both in the short and medium to long term. A better understanding of the pathophysiological mechanisms of Post-COVID manifestations that affect the autonomic nervous system, and targeted therapeutic management could help reduce the sequelae of COVID-19, especially if we act in the earliest phases of the disease.
Top-30
Journals
|
1
2
3
4
|
|
|
Frontiers in Neurology
4 publications, 6.67%
|
|
|
Cureus
4 publications, 6.67%
|
|
|
Journal of Clinical Medicine
3 publications, 5%
|
|
|
Cardiopulmonary Physical Therapy Journal
3 publications, 5%
|
|
|
Frontiers in Neuroscience
2 publications, 3.33%
|
|
|
World Journal of Clinical Cases
2 publications, 3.33%
|
|
|
COVID
1 publication, 1.67%
|
|
|
Viruses
1 publication, 1.67%
|
|
|
Frontiers in Sports and Active Living
1 publication, 1.67%
|
|
|
Seminars in Respiratory and Critical Care Medicine
1 publication, 1.67%
|
|
|
Psychiatry and Clinical Neurosciences
1 publication, 1.67%
|
|
|
Guides Newsletter
1 publication, 1.67%
|
|
|
Healthcare
1 publication, 1.67%
|
|
|
Acta Neuropathologica
1 publication, 1.67%
|
|
|
Molecular and Cellular Biochemistry
1 publication, 1.67%
|
|
|
BMJ Open
1 publication, 1.67%
|
|
|
Journal of the Neurological Sciences
1 publication, 1.67%
|
|
|
Acta medica Lituanica
1 publication, 1.67%
|
|
|
Nature Reviews Neuroscience
1 publication, 1.67%
|
|
|
European Journal of Pain
1 publication, 1.67%
|
|
|
Clinical Microbiology and Infection
1 publication, 1.67%
|
|
|
Advances in Rehabilitation Science and Practice
1 publication, 1.67%
|
|
|
Journal of Personalized Medicine
1 publication, 1.67%
|
|
|
International Journal of Molecular Sciences
1 publication, 1.67%
|
|
|
European Journal of Pediatrics
1 publication, 1.67%
|
|
|
Infection and Chemotherapy
1 publication, 1.67%
|
|
|
BMJ
1 publication, 1.67%
|
|
|
Journal of Korean Medical Science
1 publication, 1.67%
|
|
|
American Journal of Medical Quality
1 publication, 1.67%
|
|
|
1
2
3
4
|
Publishers
|
2
4
6
8
10
12
|
|
|
Springer Nature
11 publications, 18.33%
|
|
|
MDPI
9 publications, 15%
|
|
|
Frontiers Media S.A.
8 publications, 13.33%
|
|
|
Elsevier
5 publications, 8.33%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
4 publications, 6.67%
|
|
|
Cold Spring Harbor Laboratory
3 publications, 5%
|
|
|
Wiley
2 publications, 3.33%
|
|
|
Baishideng Publishing Group
2 publications, 3.33%
|
|
|
BMJ
2 publications, 3.33%
|
|
|
SAGE
2 publications, 3.33%
|
|
|
Georg Thieme Verlag KG
1 publication, 1.67%
|
|
|
American Medical Association (AMA)
1 publication, 1.67%
|
|
|
Vilnius University Press
1 publication, 1.67%
|
|
|
XMLink
1 publication, 1.67%
|
|
|
Korean Academy of Medical Sciences
1 publication, 1.67%
|
|
|
Media Sphere Publishing House
1 publication, 1.67%
|
|
|
Far Eastern Scientific Center Of Physiology and Pathology of Respiration
1 publication, 1.67%
|
|
|
AME Publishing Company
1 publication, 1.67%
|
|
|
Czech Society of Cardiology
1 publication, 1.67%
|
|
|
2
4
6
8
10
12
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.